Sanofi-Aventis Argentina S.A.

What Sanofi-Aventis Argentina S.A. does

Sanofi-Aventis Argentina S.A. operates as the Argentine subsidiary of Sanofi S.A. (EPA:SAN), a publicly listed global pharmaceutical group. The entity runs pharma and vaccines operations across the Cono Sur region (Argentina, Chile, Paraguay) with 450+ employees, distributing innovative medicines across eight therapeutic areas — respiratory health, dermatology, central nervous system, rare diseases, neoplasms and immunological diseases, digestive tract and metabolism, and rare blood diseases — alongside pediatric and adult vaccines. Its go-to-market combines enterprise field sales to hospitals and healthcare institutions, pharmacy-channel distribution for prescription products, and regulatory engagement with ANMAT, Argentina's pharmaceutical regulator.

The company's core production asset is a biotechnological manufacturing plant at Parque Industrial Pilar, Argentina, where hepatitis B antigen is produced using a proprietary last-generation process for the global Sanofi vaccine supply chain. The antigen is exported to Sanofi laboratories in France, where it is combined with other antigens to produce the hexavalent pediatric vaccine (protecting against six diseases), which is subsequently distributed globally including back into Argentina. The subsidiary also markets nirsevimab, a monoclonal antibody approved by ANMAT in January 2024 for passive immunization of infants against RSV-caused bronchiolitis, supported by a published 82% reduction in infant RSV hospitalizations in The Lancet. Supporting platforms include Campus Sanofi for healthcare professional education and the Sanofi Studies portal hosting 100+ active clinical investigations.

Revenue mechanics rely on institutional and retail pharmaceutical sales within Argentina, regional Cono Sur pharma distribution, and intra-group manufacturing revenue tied to global vaccine supply. The €26 million clinical research investment in Cono Sur in 2024, deployed across 756 collaborating research centers, indicates a regional R&D footprint that goes beyond a pure commercial-sales role and integrates the subsidiary into Sanofi's global clinical pipeline. Operations are wholly controlled by Sanofi Group; there is no independent fundraising, cap table, or external ownership dimension.

Name

Sanofi-Aventis Argentina S.A.

Legal name

Sanofi-Aventis Argentina S.A.

Website

https://sanofi-aventis.com.ar

Company type

Public

Operating status

Operating

Headcount range

1–10 employees

Short description

Sanofi-Aventis Argentina S.A. is the Argentine subsidiary of global pharma group Sanofi S.A., distributing innovative medicines and vaccines across Argentina, Chile, and Paraguay, and operating a biomanufacturing plant in Pilar that produces hepatitis B antigen for Sanofi's global hexavalent pediatric vaccine.

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)

akta.pro secondary industries

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Pharmaceutical products
• Vaccine manufacturing
• Biotechnology research
• Monoclonal antibodies
• Clinical research

Headquarters

HQ city

Argentina

HQ country

Argentina

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Development and sale of innovative medicines and treatments across multiple therapeutic areas including respiratory health, dermatology, CNS, rare diseases, neoplasms, immunological diseases, and digestive tract/metabolism
2. Vaccines: Development, production and distribution of pediatric and adult vaccines including the hexavalent vaccine produced in Argentina and exported to France for global distribution

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Sanofi-Aventis Argentina S.A. develops, manufactures, and distributes pharmaceutical products and vaccines across multiple therapeutic areas including respiratory health, dermatology, CNS, rare diseases, neoplasms, immunological diseases, and digestive/metabolic disorders. The company operates a manufacturing plant in Pilar, Argentina that produces hepatitis B antigen for the global hexavalent pediatric vaccine, and distributes innovative medicines and vaccines including the nirsevimab monoclonal antibody for infant RSV protection to healthcare institutions, hospitals, and pharmacies in Argentina.

Product overview

Sanofi Argentina operates as a pharmaceutical and healthcare company with a manufacturing plant in Pilar Industrial Park, Argentina. The company's core products include the hexavalent pediatric vaccine (manufacturing the hepatitis B antigen locally and exporting to France) and nirsevimab (monoclonal antibody for infant RSV protection). Supporting platforms include Campus Sanofi (healthcare professional portal) and Sanofi Studies (clinical research information platform). The company conducts over 100 active clinical investigations across therapeutic areas with 450+ employees in Argentina, Chile, and Paraguay.

Differentiator

Problem solved

Functional benefit

Products and services

• Vacuna Hexavalente (Hexavalent Vaccine) Pediatric hexavalent acellular vaccine that protects against 6 diseases. The hepatitis B antigen is produced in Sanofi's Pilar, Argentina plant and exported to France for combination with other antigens to create the final vaccine, which is then distributed globally including back to Argentina.
• Nirsevimab Monoclonal antibody approved by ANMAT for protecting infants against bronchiolitis caused by RSV (Respiratory Syncytial Virus) through passive immunization. Real-world evidence published in The Lancet shows an 82% reduction in infant hospitalizations for RSV.
• Antígeno de Hepatitis B (Hepatitis B Antigen) Biotechnological product manufactured at Sanofi's Pilar Industrial Park plant in Argentina using cutting-edge biotechnology processes. Exported to Sanofi laboratories in France for incorporation into the hexavalent pediatric vaccine that protects against 6 diseases.

Quantifiable outcome

• 82% reduction in infant hospitalizations for RSV with nirsevimab (published in The Lancet)

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• GSK Argentina: Argentine operations of a global vaccines-and-specialty-pharma major. Directly comparable as a competing multinational with both a vaccine portfolio (including pediatric combinations) and a respiratory/immunology specialty pharma book in Argentina.
• AstraZeneca Argentina: Local subsidiary of a global biopharma with an oncology, respiratory, and vaccines footprint in Argentina. Comparable multinational pharma structure competing for the same hospital accounts, ANMAT approvals, and clinical research partnerships.
• Bayer Argentina: Local subsidiary of a global life-sciences company with pharmaceuticals (cardiovascular, women's health, oncology) plus crop science and consumer health. Comparable as a multinational operating a diversified pharma business through Argentine healthcare channels.
• Johnson & Johnson Innovative Medicine Argentina: Argentine pharmaceutical arm of J&J, selling innovative medicines in oncology, immunology, neuroscience, and pulmonary hypertension through hospital channels. Comparable as a multinational pharma subsidiary with similar specialty-pharma GTM.
• MSD (Merck & Co.) Argentina: Local subsidiary of a top-tier global pharma selling vaccines, oncology, and specialty medicines through Argentine hospital and pharmacy channels. Comparable multinational pharma presence with similar GTM and regulatory exposure (ANMAT).
• Novartis Argentina: Argentine subsidiary of a global pharmaceutical major with a broad innovative-medicines portfolio across cardiovascular, respiratory, immunology, and rare diseases. Directly comparable as another multinational pharma subsidiary operating through enterprise field sales to Argentine healthcare institutions.
• Pfizer Argentina: Argentine subsidiary of a global pharmaceutical leader, competing head-to-head with Sanofi Argentina across vaccines, oncology, respiratory, and rare disease portfolios and selling through the same hospital/pharmacy channels. Highly comparable as a multinational pharma's local operating entity.
• Boehringer Ingelheim Argentina: Argentine subsidiary of a global pharma with respiratory, cardiometabolic, and specialty franchises. Comparable multinational pharma structure selling innovative medicines through Argentine hospital and specialty channels with similar ANMAT regulatory pathway.
• Roche Argentina: Local subsidiary of a global biopharma company with a strong oncology, respiratory and specialty-care presence in Argentina. Directly comparable multinational pharma structure with hospital-led GTM and biologic manufacturing/sourcing globally.
• AbbVie Argentina: Argentine subsidiary of a global biopharma with immunology, oncology, neuroscience, and aesthetics franchises. Comparable multinational pharma structure selling specialty biologics through the same Argentine hospital and payer ecosystem.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sanofi-aventis-argentina-s.a.

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanofi-Aventis Argentina S.A.